For the quarter ending 2025-09-30, JANX made $10,000K in revenue. -$23,498K in net income. Net profit margin of -234.98%.
| Income Statement | 2025-09-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 10,000 | - | 3,383 | 439 |
| Research and development | 34,629 | 25,055 | 16,591 | 18,614 |
| General and administrative | 10,622 | 9,842 | 7,793 | 17,667 |
| Total operating expenses | 45,251 | 34,897 | 24,385 | 36,281 |
| Loss from operations | -35,251 | -34,897 | -21,002 | -35,842 |
| Interest income | 10,938 | 11,389 | 7,357 | 7,783 |
| Total other income | 10,938 | 11,389 | 7,357 | 7,783 |
| Net loss | -24,313 | -23,508 | -13,645 | -28,059 |
| Unrealized gain on available-for-sale securities, net | 815 | 1,593 | -2,650 | 9,447 |
| Comprehensive loss | -23,498 | -21,915 | -16,295 | -18,612 |
| Earnings per share, basic, total | -0.39 | -0.38 | -0.257 | -0.51 |
| Net loss per common share, diluted | -0.39 | -0.38 | -0.257 | -0.51 |
| Weighted average number of shares outstanding, diluted | 62,023,685 | 61,791,721 | -292,396.667 | 54,628,670 |
| Weighted-average shares of common stock outstanding, basic | 62,023,685 | 61,791,721 | -292,396.667 | 54,628,670 |
Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX)